Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
Ocedurenone | C28H30ClN5O2 | CID 75593324 - PubChem
Ocedurenone | TargetMol
Ocedurenone | CAS NO.:1359969-24-6 | GlpBio
ocedurenone | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY
Ocedurenone (KBP-5074) | CAS 1359969-24-6 | AbMole BioScience ...
Ocedurenone - Wikipedia
(PDF) Pharmacokinetics and Drug–Drug Interaction of Ocedurenone (KBP ...
Pharmacokinetics and Drug-Drug Interaction of Ocedurenone (KBP-5074) in ...
Pharmacokinetics and Drug–Drug Interaction of Ocedurenone (KBP-5074) in ...
Novo Nordisk to Acquire Ocedurenone from KBP Biosciences | Contract Pharma
Ocedurenone SBP较安慰剂组变化 - 2023年04月 - 行业研究数据 - 小牛行研
Novo Nordisk 以 13 億美元收購 KBP Biosciences 的 ocedurenone 藥物 - 財報狗
Novo Nordisk to acquire ocedurenone from KBP Biosciences; Hankang ...
Abstract 13133: Effect of Ocedurenone in Patients With Uncontrolled ...
Ocedurenone (KBP-5074) Featured at the 19th Cardiovascular Clinical ...
شركة نوڤو نورديسك تسعى إلى شراء Ocedurenone لارتفاع ضغط الدم مقابل 1.3 ...
Arithmetic mean (±SD) plasma concentrations of ocedurenone following ...
Novo Nordisk takes US$816M hit as ocedurenone trial flops | HealthCare ...
Novo seeks $830M from KBP in ocedurenone fraud case
Novo Nordisk Faces Setback with Ocedurenone Drug Trial - CTOL Digital ...
Novo Nordisk Drops Ocedurenone After Trial Failure and Financial Losses ...
诺和诺德高血压药物，OcedurenoneⅢ期临床失败_患者_受体_难治性
1359969-24-6 - ChemicalBook
【速递】超8亿美元减值（13亿美元收购），诺和诺德MR拮抗剂III期临床失败|高血压_新浪财经_新浪网
ocedurenone-drug information-NextBiopharm™-ByDrug-Pharmcube Database
Ocedurenone|KBP-5074——药研档案
Canrenone-d4
13亿美元！诺和诺德加码肾科布局，收购亨利医药MRA拮抗剂ocedurenone_腾讯新闻
诺和诺德：Ocedurenone三期临床失败，13亿美元从亨利医药引进_CPHI制药在线移动官网
(PDF) Efficacy and Safety of Ocedurenone: Subgroup Analysis of the ...
损失8.16亿美元！诺和诺德终止一款肾病新药临床医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
频频出手！诺和诺德加速对外布局医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
【速递】超8亿美元减值（13亿美元收购），诺和诺德MR拮抗剂III期临床失败医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
Oudenone | Antibiotic | MedChemExpress
The Complexity of Resistant and Refractory Hypertension.pptx
TCMSP - Traditional Chinese Medicine Systems Pharmacology Database and ...
减肥药巨头又有新动作！13亿美元收购高血压药物Ocedurenone_手机新浪网
进一步加强药物线！“减肥神药”制造商13亿美元收购高血压药物Ocedurenone
诺和：Cagrisema头对头Tirzepatide挑战礼来医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
Ocella: Package Insert / Prescribing Information / MOA
Resistant Hypertension Management. 2024pptx | PPTX
Novo Nordisk agrees $1.3bn hypertension acquisition | News | European ...
403 Forbidden
《收購》諾和諾德(Novo Nordisk)瘦瘦針大賣後的下一步? 400億台幣買下新加坡KBP高血壓候選口服新藥ocedurenone ...
产品展厅 - 上海芮晖化工科技有限公司
KBP-5074 Effect on proteinuria in a pre-clinical rodent model ...
Finerenone Finally Finishing off Spironolactone? — NephJC
BioWorld, June 28, 2024
New Pharmacological Agents for Arrhythmias | Circulation: Arrhythmia ...
全球科技早报｜苹果CEO库克到访成都；诺和诺德13亿美元收购高血压药物Ocedurenone；领英裁员668人；Midjourney专注二次元 ...
Oxandrolone
노보, 고혈압치료제 후보 오세두레논 13억 달러에 인수 - 뉴스더보이스헬스케어
Ocedurenone: A Novel Therapy for Uncontrolled Hypertension in Advanced ...
诺和诺德发布2023年前9个月财报医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
Urodiolenone | Sesquiterpene | MedChemExpress
Laura Cecconi on LinkedIn: Novo Nordisk Buys Hypertension Drug ...
The Ross Procedure: One Patient, Two Valves - by Alex C.
Article keywords： cardiovascular kidney disease uncontrolled ...
Novo Nordisk Acquires Ocedurenone: Breakthrough Drug for Uncontrolled ...
Mineralocorticoid receptor antagonists and reno‐protection: What's the ...
Acorenone B: AChE and BChE Inhibitor as a Major Compound of the ...
A Comprehensive Overview of the Antibiotics Approved in the Last Two ...
Enantioselective 1,3-Dipolar Cycloadditions of α-Methylene Lactams to ...
Mineralocorticoid receptor - Wikipedia
Novo Nordisk Successfully Completes Phase 2 Trial With CagriSema In ...
Ondansetron ODT: Package Insert / Prescribing Info / MOA
诺和诺德下调2025全年业绩和盈利预期_CPHI制药在线
Trials That Missed the Mark in 2024 - Navigating the Complex Landscape ...
Molecular pharmacology of mineralocorticoid receptor antagonists
Design, Synthesis, and Antibacterial Evaluation of Oxazolidinones with ...
WO2000013503A1 - Microcapsule formulations - Google Patents
Hypertension In Chronic Kidney Disease—Treatment Standard 2024 – TUYDC
Obacunone, a Promising Phytochemical Triterpenoid: Research Progress on ...
13亿美元！诺和诺德引进一款KBP开发的3期临床新药医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
These highlights do not include all the information needed to use ...
A Review of Wound Healing Mechanisms of Natural... | F1000Research
Solubility and Bioavailability Enhancement of Oridonin: A Review - PMC
EP0227844A1 - Antiviral drug - Google Patents
US6479541B1 - Amiodarone-containing parenteral administration - Google ...
Transcatheter Tricuspid Valve Replacement With EVOQUE and Mitral Valve ...
Ondansetron: Package Insert / Prescribing Information / MOA
Unilateral Ureteral Obstruction as a Model to Investigate Fibrosis ...
13亿美元，诺和诺德收购新型降压药，产品已处于临床3期_开发_治疗_药物
DailyMed - ONDANSETRON tablet, orally disintegrating
Novo Nordisk Aktie: Vermögenssperre gegen KBP bleibt
Octreotide - brand name list from Drugs.com
Subcutaneous injection (Procedure, sites and complications) | PPTX ...
Absolute configuration of odorine. - Abstract - Europe PMC
阿莫奎尼(Ocedurenone) - 药物靶点：MR_在研适应症：肾病，肾性高血压_专利_临床_研发
b. A schematic 2D interaction diagrams showing the binding contacts of ...
Activity of Antiseptics Against Pseudomonas aeruginosa and Its ...
Archives des Actualité - YouTechCare
Developing an activity and absorption-based quality control platform ...
From Plant to Chemistry: Sources of Active Opioid Antinociceptive ...
The WATCHMAN Procedure: A One Time Implant for a Lifetime of Stroke ...
The Journal of Organic Chemistry Vol. 65 No. 12 - ACS Publications
DailyMed - ONDANSETRON- ondansetron hydrochloride solution
Advances in oligonucleotide drug delivery - PMC
The Pharmaceutical Industry in 2020. An Analysis of FDA Drug Approvals ...
Mineralocorticoid Receptor | 盐皮质激素受体 | 拮抗剂 激动剂 | MCE
DailyMed - ONDANSETRON HYDROCHLORIDE tablet, film coated ONDANSETRON ...
